<DOC>
	<DOCNO>NCT01277601</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy tenofovir disoproxil fumarate ( TDF ) plus peginterferon α-2a ( Peg-IFN ) combination therapy 48 week versus standard care TDF monotherapy Peg-IFN monotherapy 48 week non-cirrhotic adult chronic hepatitis B virus ( HBV ) determine loss hepatitis B surface antigen ( HBsAg ) . The study consist 2 phase participant TDF+Peg-IFN 48 Weeks , TDF 48 Weeks + Peg-IFN 16 Weeks , Peg-IFN 48 Weeks group . Following initial 48 week treatment , participant group monitor 24 week sign worsen HBV , meet TDF retreatment flare management criterion eligible receive TDF monotherapy retreatment phase , Week 120 .</brief_summary>
	<brief_title>Efficacy &amp; Safety Tenofovir Disoproxil Fumarate ( TDF ) Plus Peginterferon α-2a ( Peg-IFN ) Versus TDF Peg-IFN Monotherapy Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Adults ( age 1875 ) chronic HBV ( positive serum hepatitis B surface antigen ( HBsAg ) HBV DNA least 6 month ) prior baseline AntiHBV treatmentnaive adult ; adult take oral antiHBV nucleoside therapy last dose ≥ 24 week prior screen also eligible . Positive negative hepatitis B e antigen ( HBeAg ) HBV DNA ≥ 20,000 IU/ml ( HBeAgpositive participant ) ≥ 2,000 IU/ml ( HBeAgnegative participant ) Alanine aminotransferase ( ALT ) &gt; 54 U/L ≤ 400 U/L men &gt; 36 U/L ≤ 300 U/L woman Creatinine clearance ≥ 70 mL/min Negative serum pregnancy test female childbearing potential Sexually active female childbearing potential must agree use protocolrecommended method contraception throughout study 30 day follow last dose study medication Lactating female must agree discontinue nurse initiation study investigational medicinal product Known bridging fibrosis cirrhosis and/or decompensated liver disease Evidence hepatocellular carcinoma Significant kidney , heart , lung , neurological , autoimmune disease , bone disease ( eg , osteomalacia , chronic osteomyelitis , osteogenesis imperfecta , osteochondrosis , multiple bone fracture ) Absolute neutrophil count &lt; 1,500/mm^3 , platelet &lt; 100,000/mm^3 , hemoglobin &lt; 10 g/dL ( female ) &lt; 11 g/dL ( male ) History severe depression severe psychiatric disease Thyroid dysfunction Coinfection HIV , hepatitis C virus ( HCV ) hepatitis D virus ( HDV ) Pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>Hep B</keyword>
	<keyword>Non cirrhotic</keyword>
	<keyword>Tenofovir disoproxil fumarate ( TDF )</keyword>
	<keyword>Peginterferon α-2a ( Peg-IFN )</keyword>
</DOC>